Cargando…

Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan

Drug pricing methods vary extensively across countries. Japan calculates drug prices using cost accounting and based on the efficacy of similar drugs. This study investigated the relationship between drug prices and their clinical efficacy and usefulness using public information on anticancer drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Okabe, Ayano, Hayashi, Haruto, Maeda, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955512/
https://www.ncbi.nlm.nih.gov/pubmed/36826098
http://dx.doi.org/10.3390/curroncol30020137
_version_ 1784894364691988480
author Okabe, Ayano
Hayashi, Haruto
Maeda, Hideki
author_facet Okabe, Ayano
Hayashi, Haruto
Maeda, Hideki
author_sort Okabe, Ayano
collection PubMed
description Drug pricing methods vary extensively across countries. Japan calculates drug prices using cost accounting and based on the efficacy of similar drugs. This study investigated the relationship between drug prices and their clinical efficacy and usefulness using public information on anticancer drugs reimbursed by the National Health Insurance price listing between January 2009 and March 2020. We investigated drug characteristics, prices, and clinical benefits based on overall survival (OS) and progression-free survival (PFS). Eighty anticancer drugs were approved in Japan during the study period. The largest number (28 drugs, 35.0%) was approved based on PFS, 18 (22.5%) were approved based on OS, and 13 (16.3%) based on the response rate. The mean (±SD) drug price was JPY 88,416.2 (±148,974.7), while the median drug price (with quartiles) was JPY 21,694 (JPY 4855.0–JPY 93,396.8). Drug prices were significantly higher for PFS than for OS, while cost index—the drug price to extend PFS or OS by one day—did not differ significantly between PFS and OS. The relationship between the 46 drugs approved based on OS or PFS and their prices was examined. A correlation was found between drug prices and their clinical usefulness in terms of OS but not PFS.
format Online
Article
Text
id pubmed-9955512
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99555122023-02-25 Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan Okabe, Ayano Hayashi, Haruto Maeda, Hideki Curr Oncol Article Drug pricing methods vary extensively across countries. Japan calculates drug prices using cost accounting and based on the efficacy of similar drugs. This study investigated the relationship between drug prices and their clinical efficacy and usefulness using public information on anticancer drugs reimbursed by the National Health Insurance price listing between January 2009 and March 2020. We investigated drug characteristics, prices, and clinical benefits based on overall survival (OS) and progression-free survival (PFS). Eighty anticancer drugs were approved in Japan during the study period. The largest number (28 drugs, 35.0%) was approved based on PFS, 18 (22.5%) were approved based on OS, and 13 (16.3%) based on the response rate. The mean (±SD) drug price was JPY 88,416.2 (±148,974.7), while the median drug price (with quartiles) was JPY 21,694 (JPY 4855.0–JPY 93,396.8). Drug prices were significantly higher for PFS than for OS, while cost index—the drug price to extend PFS or OS by one day—did not differ significantly between PFS and OS. The relationship between the 46 drugs approved based on OS or PFS and their prices was examined. A correlation was found between drug prices and their clinical usefulness in terms of OS but not PFS. MDPI 2023-02-01 /pmc/articles/PMC9955512/ /pubmed/36826098 http://dx.doi.org/10.3390/curroncol30020137 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Okabe, Ayano
Hayashi, Haruto
Maeda, Hideki
Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
title Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
title_full Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
title_fullStr Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
title_full_unstemmed Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
title_short Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
title_sort correlation of anticancer drug prices with outcomes of overall survival and progression-free survival in clinical trials in japan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955512/
https://www.ncbi.nlm.nih.gov/pubmed/36826098
http://dx.doi.org/10.3390/curroncol30020137
work_keys_str_mv AT okabeayano correlationofanticancerdrugpriceswithoutcomesofoverallsurvivalandprogressionfreesurvivalinclinicaltrialsinjapan
AT hayashiharuto correlationofanticancerdrugpriceswithoutcomesofoverallsurvivalandprogressionfreesurvivalinclinicaltrialsinjapan
AT maedahideki correlationofanticancerdrugpriceswithoutcomesofoverallsurvivalandprogressionfreesurvivalinclinicaltrialsinjapan